Search and analyze individual stocks with comprehensive metrics
Lincoln Pharmaceuticals Ltd
Fundamental Score
Lincoln Pharmaceuticals Ltd Share Price Live NSE/BSE
Profitability Metrics
Return on Equity
Return on Capital Employed
Operating Profit Margin (5Y)
Dividend Yield
Valuation Metrics
Price to Earnings
Market Capitalization
Industry P/E
Growth Metrics
YoY Quarterly Profit Growth
YoY Quarterly Sales Growth
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Financial Health
Debt to Equity
Interest Coverage
Free Cash Flow (5Y)
Ownership Structure
Promoter Holding
FII Holding
DII Holding
Pledged Percentage
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Market Data Analysis & Educational Insights
Educational evaluation of LINCOLN across key market metrics for learning purposes.
Positive Indicators
7 factors identified
Excellent ROCE Performance (17.28%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance. This indicates quality business fundamentals.
Strong Operating Margins (18.17%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages. This indicates sustainable profitability potential.
Attractive Valuation (P/E: 12.68 vs Industry: 31.77)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity if fundamentals support the business case.
Debt-Free Balance Sheet (D/E: 0.00)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns and flexibility for growth investments.
Strong Interest Coverage (71.86x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk and strong debt servicing capability.
Strong Cash Generation (₹214.56 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral, reducing forced-selling risk.
Analysis: Absence of share pledging eliminates potential forced-selling pressure during market stress.
Risk Factors
2 factors identified
Profit Decline Concern (-24.12%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes. Monitor for recovery signs and management guidance.
Limited Institutional Interest (FII+DII: 4.74%)
Observation: Low institutional participation may affect liquidity and visibility.
Analysis: Limited institutional interest may indicate size constraints or visibility issues in the investment community.
Loading Peer Comparison
Finding companies in the Pharmaceuticals sector...
Financial Statements
Comprehensive financial data for Lincoln Pharmaceuticals Ltd
About LINCOLN
Business Overview
Lincoln Pharmaceuticals Limited engages in manufacturing and trading of pharmaceutical products in India. The company offers products in the areas of anticold, antibiotic, otolaryngology, pain management, gastro, anti-malarial, anti-fungal, corticosteroids and cosmo-derma, anti-diabetic, anti-hypertensive, gynecology, cardio and CNS, respiratory system, and dyslipidemic; and branded generics. It also exports its products to approximately 60 countries, including Europe, Canada, Latin and North America, Africa, the Asia Pacific, and South East Asia. Lincoln Pharmaceuticals Limited was incorporated in 1979 and is based in Ahmedabad, India.
Company Details
Key Leadership
Corporate Events
LINCOLN Stock Details & Analysis
Key Financial Metrics
Growth & Valuation
Frequently Asked Questions
What is the current price of Lincoln Pharmaceuticals Ltd (LINCOLN)?
As of 16 Jan 2026, 10:12 am IST, Lincoln Pharmaceuticals Ltd (LINCOLN) is currently trading at ₹479.40. The stock has a market capitalization of ₹1.01K (Cr).
Is LINCOLN share price Overvalued or Undervalued?
LINCOLN is currently trading at a P/E ratio of 12.68x, compared to the industry average of 31.77x. Based on this relative valuation, the stock appears to be Undervalued against its sector peers.
What factors affect the Lincoln Pharmaceuticals Ltd share price?
Key factors influencing LINCOLN's price include its quarterly earnings growth (Sales Growth: 1.33%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Lincoln Pharmaceuticals Ltd a good stock for long-term investment?
Lincoln Pharmaceuticals Ltd shows a 5-year Profit Growth of 9.50% and an ROE of 12.82%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.00 before investing.
How does Lincoln Pharmaceuticals Ltd compare with its industry peers?
Lincoln Pharmaceuticals Ltd competes with major peers in the Pharmaceuticals. Investors should compare LINCOLN's P/E of 12.68x and ROE of 12.82% against the industry averages to determine its competitive standing.
What is the P/E ratio of LINCOLN and what does it mean?
LINCOLN has a P/E ratio of 12.68x compared to the industry average of 31.77x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹13 for every ₹1 of annual earnings.
How is LINCOLN performing according to Bull Run's analysis?
LINCOLN has a Bull Run fundamental score of 51.5/100, which indicates moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters including profitability, growth metrics, and valuation ratios.
What sector and industry does LINCOLN belong to?
LINCOLN operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Lincoln Pharmaceuticals Ltd.
What is Return on Equity (ROE) and why is it important for LINCOLN?
LINCOLN has an ROE of 12.82%, which shows decent profitability but room for improvement. Return on Equity measures how efficiently Lincoln Pharmaceuticals Ltd generates profits from shareholders' equity.
How is LINCOLN's debt-to-equity ratio and what does it indicate?
LINCOLN has a debt-to-equity ratio of 0.00, which indicates conservative financing with low financial risk. A ratio below 1.0 generally indicates conservative financing.
What is LINCOLN's dividend yield and is it a good dividend stock?
LINCOLN offers a dividend yield of 0.36%, which means you receive ₹0.36 annual dividend for every ₹100 invested.
How has LINCOLN grown over the past 5 years?
LINCOLN has achieved 5-year growth rates of: Sales Growth 10.03%, Profit Growth 9.50%, and EPS Growth 9.47%.
What is the promoter holding in LINCOLN and why does it matter?
Promoters hold 49.78% of LINCOLN shares, with 0.00% of promoter shares pledged. High promoter holding often indicates strong management confidence.
What is LINCOLN's market capitalization category?
LINCOLN has a market capitalization of ₹1015 crores, placing it in the Small-cap category.
How volatile is LINCOLN stock?
LINCOLN has a beta of N/A. A beta > 1 suggests the stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is the 52-week high and low for LINCOLN?
LINCOLN has a 52-week high of ₹N/A and low of ₹N/A.
What is LINCOLN's operating profit margin trend?
LINCOLN has a 5-year average Operating Profit Margin (OPM) of 18.17%, indicating the company's operational efficiency.
How is LINCOLN's quarterly performance?
Recent quarterly performance shows YoY Sales Growth of 1.33% and YoY Profit Growth of -24.12%.
What is the institutional holding pattern in LINCOLN?
LINCOLN has FII holding of 4.73% and DII holding of 0.01%. Significant institutional holding often suggests professional confidence in the stock.